Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care

被引:0
|
作者
John D. Hainsworth
F. Anthony Greco
机构
[1] Sarah Cannon Research Institute,
[2] Sarah Cannon Research Institute,undefined
来源
Virchows Archiv | 2014年 / 464卷
关键词
Gene expression profiling; Cancer of unknown primary site; Immunohistochemical stains; Molecular diagnostics;
D O I
暂无
中图分类号
学科分类号
摘要
Carcinoma of unknown primary site (CUP) is diagnosed in approximately 3 % of patients with advanced cancer, and most patients have traditionally been treated with empiric chemotherapy. As treatments improve and become more specific for individual solid tumor types, therapy with a single empiric combination chemotherapy regimen becomes increasingly inadequate. Gene expression profiling (GEP) is a new diagnostic method that allows prediction of the site of tumor origin based on gene expression patterns retained from the normal tissues of origin. In blinded studies in tumors of known origin, GEP assays correctly identified the site of origin in 85 % of cases and compares favorably with immunohistochemical (IHC) staining. In patients with CUP, GEP is able to predict a site of origin in >95 % of patients versus 35–55 % for IHC staining. Although confirmation of the accuracy of these predictions is difficult, the diagnoses made by IHC staining and GEP are identical in 77 % of cases when IHC staining predicts a single primary site. GEP diagnoses appear to be most useful when IHC staining is inconclusive. Site-specific treatment of CUP patients based on GEP and/or IHC predictions appears to improve overall outcomes; patients predicted to have treatment-sensitive tumor types derived the most benefit. GEP adds to the diagnostic evaluation of patients with CUP and should be included when IHC staining is unable to predict a single site of origin. Site-specific treatment, based on tissue of origin diagnosis, should replace empiric chemotherapy in patients with CUP.
引用
收藏
页码:393 / 402
页数:9
相关论文
共 50 条
  • [21] Cancer of Unknown Primary or Unrecognized Adnexal Skin Primary Carcinoma? Limitations of Gene Expression Profiling Diagnosis Reply
    Chiang, Wendy M.
    Laver, Nora
    Nystrom, John S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1480 - 1481
  • [22] Identification of cancer of unknown primary with gene expression profiling.
    Li, H.
    Qu, K.
    Tokoro, K.
    Ren, Y.
    Liu, J. Y.
    Sferruzza, A.
    Bender, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 553S - 553S
  • [23] Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients (pts) with carcinoma of unknown primary site (CUP): Results of a prospective Sarah Cannon Research Institute (SCRI) trial
    Greco, Frank A.
    Rubin, Mark S.
    Boccia, Ralph V.
    Scola, Michael A.
    Spigel, David R.
    Raby, Samuel
    Chirwa, Thabiso W.
    Quinn, Raven
    Schnabel, Catherine A.
    Erlander, Mark G.
    Hainsworth, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [24] On multiple testing,validation of gene expression profiling,and translational research
    Xianjin XIE Department of Clinical Sciences Simmons Comprehensive Cancer Center University of Texas Southwestern Medical Center DallasTexas USA ZHAO Yupei and CHEN Ge Department of General Surgery Peking Union Medical College Hospital Beijing China
    中华医学杂志(英文版), 2008, (13) : 1247 - 1248
  • [25] EMPIRIC CHEMOTHERAPY IN PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY SITE
    SPORN, JR
    GREENBERG, BR
    AMERICAN JOURNAL OF MEDICINE, 1990, 88 (01): : 49 - 55
  • [26] On multiple testing, validation of gene expression profiling, and translational research
    Xie, Xian-jin
    CHINESE MEDICAL JOURNAL, 2008, 121 (13) : 1247 - 1247
  • [27] ANALYSIS OF 24 PATIENTS WITH CARCINOMA OF UNKNOWN PRIMARY SITE
    Kudo, C.
    Niitani, T.
    Sugiyama, K.
    ANNALS OF ONCOLOGY, 2013, 24 : 63 - 63
  • [28] Gemcitabine and cisplatin in patients with carcinoma of unknown primary site
    Isik, Metin
    Seker, Mehmet M.
    Odabas, Hatice
    Kos, Fahriye T.
    Uncu, Dogan
    Zengin, Nurullah
    MEDICAL ONCOLOGY, 2011, 28 (02) : 591 - 596
  • [29] Gemcitabine and cisplatin in patients with carcinoma of unknown primary site
    Metin Isik
    Mehmet M. Seker
    Hatice Odabas
    Fahriye T. Kos
    Dogan Uncu
    Nurullah Zengin
    Medical Oncology, 2011, 28 : 591 - 596
  • [30] Gene Expression Microarray-Based Diagnostic Test May Identify Primary Tumor Site in Patients with Carcinoma of Unknown Primary (CUP)
    Medeiros, F.
    Kolbert, C.
    Rohakhtar, F. Rakhshan
    Lindgren, T. M. Kane
    Wilson, M. J.
    Rigi, T.
    Deeter, R.
    Goetz, M. P.
    Henner, D.
    Halling, K. C.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 604 - 604